Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2026. The company reported a total income of ₹17,270 crore for FY26, reflecting a 14% year-on-year growth, excluding one-time generic lenalidomide sales in Q4FY25 and adjusted for BFI divestment gain.
In Q4FY26, Biocon‘s total income stood at ₹4,569 crore, marking a 10% increase compared to the previous year, after adjusting for one-time generic lenalidomide sales. The company’s EBITDA for the quarter was ₹1,073 crore, up 29% year-on-year, with a margin of 23%. Net profit before exceptional items for the quarter was ₹179 crore, up 64% from the previous year.
For the full fiscal year, Biocon’s operating revenue reached ₹16,927 crore, a 13% increase year-on-year. The EBITDA for FY26 was ₹3,798 crore, up 25% from the previous year, with an EBITDA margin of 22%, up 200 basis points on a like-to-like basis. The net profit before exceptional items for the year was ₹436 crore, showing a significant increase of 323% year-on-year.
Biocon’s biosimilars segment reported revenues of ₹10,431 crore for FY26, up 16% year-on-year, while the generics segment saw a 17% increase in revenue to ₹3,168 crore. The research services segment, Syngene, reported a 3% growth in revenue to ₹3,739 crore.
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, highlighted the company’s strong performance despite a complex geopolitical environment. She noted that the integration of the biosimilars business with generics formulations and APIs business has resulted in a stronger balance sheet and improved leverage metrics.
Shreehas Tambe, CEO & Managing Director of Biocon Limited, emphasised the successful integration of the biosimilars and generics business, which has created a unified biopharmaceutical enterprise with greater scale and capability. He noted the company’s shift from the “Preserve” phase to “Consolidate” as it sets up for sustainable growth.
The Board of Directors has recommended a final dividend of Re. 0.50 per share at the rate of 10% of the face value of the share for the financial year ending March 31, 2026.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).